Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta
Phase of Trial: Phase IV
Latest Information Update: 26 Jun 2019
Price : $35 *
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Pfizer
- 31 Jul 2018 Planned number of patients changed from 3000 to 100.
- 31 Jul 2018 Status changed from not yet recruiting to recruiting.
- 16 Jul 2018 Planned End Date changed from 21 Aug 2018 to 21 Aug 2021.